 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
NGX267
|
|
Other Names:
|
AF267B
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Inactive
|
|
Primary Medical Role:
|
Class: Selective muscarinic (M1) agonist. Preclinical data
support a dual mechanism of action. NGX267 has been shown to
stimulate M1 receptors in a fashion analogous to
acetylcholine, a neurotransmitter essential for memory and
cognitive function that is depleted when neurons, or brain
cells, degenerate. In addition, in studies in mice and
rabbits, NGX267 lowered brain levels of Aβ1-42, a toxic
peptide that is the major component of amyloid plaques.
|
|
Role in Alzheimer's Disease:
|
Potential to improve cognitive function as well as to slow
the progression of Alzheimer's disease.
|
|
Companies:
|
TorreyPines Therapeutics, Inc.
|
|
Notes:
|
NGX267 is no longer being tested for Alzheimer Disease.
This record was last updated Dec 19, 2008.
|
|
|
|
|
|
Home
